The Phase 3 trial (STAR-121) is appraising the combo against Keytruda + chemo with a third ... evaluating a combo of etru + dom + zim + Gilead’s Trodelvy (sacituzumab govitecan) in the treatment ...

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, ...

With these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers, Merck said in a statement. RAHWAY: Merck, also known as MSD outside the US and ...

Merck's diversified pipeline includes promising oncology candidates and a new pneumococcal vaccine, but lacks a ready-made Keytruda replacement ... Invest alongside the model portfolio, or ...

Tesla Model X and Tesla Model Y are big players in the electric SUV business, offering all the usual features like a high ride and a roomy interior on top of all the usual Tesla bells and whistles.

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...

Trodelvy shows consistent efficacy in metastatic triple-negative breast cancer with a 27.8% ORR and 4.8 months PFS. Enhertu demonstrates promising results in HER2-low patients post-Trodelvy, achieving ...

The European Commission (EC) has approved two new indications for Keytruda (pembrolizumab), Merck & Co’s (NYSE: MRK) anti-PD-1 therapy, in gynecologic cancers. The first approval is for Keytruda, in ...

People with relapsed or treatment-resistant classic Hodgkin Lymphoma now have FDA approval to use Keytruda. The immunotherapy treatment is proven to extend life. “The FDA approval is welcome news and ...

In a phase 3 trial, more deaths due to adverse events were reported in the Trodelvy arm compared with the chemotherapy arm. Gilead has made the decision to withdraw the accelerated approval of ...

In studies, the drug Trodelvy shrank tumors in people who'd already tried two other treatments. Gilead Sciences has acquired Immunomedics, and its breast cancer drug, Trodelvy. In studies, the drug ...